MX2024006370A - Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. - Google Patents
Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.Info
- Publication number
- MX2024006370A MX2024006370A MX2024006370A MX2024006370A MX2024006370A MX 2024006370 A MX2024006370 A MX 2024006370A MX 2024006370 A MX2024006370 A MX 2024006370A MX 2024006370 A MX2024006370 A MX 2024006370A MX 2024006370 A MX2024006370 A MX 2024006370A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- pharmaceutical composition
- treating
- preventing
- positivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190125 | 2021-11-24 | ||
| PCT/JP2022/043221 WO2023095802A1 (ja) | 2021-11-24 | 2022-11-22 | Ｔ細胞関連疾患を治療または予防するための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006370A true MX2024006370A (es) | 2024-08-19 |
Family
ID=86539431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006370A MX2024006370A (es) | 2021-11-24 | 2022-11-22 | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250352578A1 (https=) |
| EP (1) | EP4438048A4 (https=) |
| JP (1) | JPWO2023095802A1 (https=) |
| KR (1) | KR20240130083A (https=) |
| CN (1) | CN118591379A (https=) |
| CA (1) | CA3238860A1 (https=) |
| MX (1) | MX2024006370A (https=) |
| TW (1) | TW202334397A (https=) |
| WO (1) | WO2023095802A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250018033A1 (en) * | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| JPWO2024204553A1 (https=) * | 2023-03-29 | 2024-10-03 | ||
| JP2025064863A (ja) * | 2023-10-06 | 2025-04-17 | 株式会社マイオリッジ | Ｔ細胞の培養方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047003A1 (en) * | 2007-10-12 | 2009-04-16 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Method and kit for rapid isolation of human foxp3+ treg cells |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EA027531B1 (ru) | 2011-09-13 | 2017-08-31 | Игорь Ронинсон | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
| RU2015107550A (ru) | 2012-08-23 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Новые фенилпиридин/пиразинамиды для лечения рака |
| WO2014063778A1 (en) | 2012-10-08 | 2014-05-01 | Merck Patent Gmbh | 2-aminopyridine compounds |
| GB201220157D0 (en) | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| HK1213544A1 (zh) | 2012-12-10 | 2016-07-08 | 霍夫曼-拉罗奇有限公司 | 新型二环苯基-吡啶/吡嗪用於治疗癌症 |
| WO2014106606A1 (en) | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| WO2014154723A1 (en) | 2013-03-29 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyrrole derivatives for the treatment of cancer |
| WO2014194245A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| TW201605857A (zh) | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Ｃｄｋ８之醫療性抑制劑及其用途 |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2015144290A1 (en) | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| JP6521387B2 (ja) | 2014-04-18 | 2019-05-29 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP6529085B2 (ja) | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| CA3051469A1 (en) * | 2017-01-27 | 2018-08-02 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells derived from umbilical cord blood |
| CN114921468A (zh) | 2017-01-30 | 2022-08-19 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| US20210238551A1 (en) * | 2018-08-22 | 2021-08-05 | Osaka University | Method for Generating Regulatory T Cells |
| WO2020102321A1 (en) * | 2018-11-13 | 2020-05-22 | Abraham J And Phyllis Katz Cord Blood Foundation | T cells with improved mitochondrial function |
| EP3891270A1 (en) * | 2018-12-07 | 2021-10-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
| MX2021013227A (es) * | 2019-04-30 | 2022-01-06 | Univ California | Expansion ex-vivo sin microesferas de celulas t reguladoras humanas. |
| US20210373951A1 (en) | 2020-05-28 | 2021-12-02 | Samsung Electronics Co., Ltd. | Systems and methods for composable coherent devices |
| US20250018033A1 (en) * | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| EP4532697A2 (en) * | 2022-06-03 | 2025-04-09 | Beam Therapeutics Inc. | Modified regulatory t cells and methods of using the same |
| EP4596684A1 (en) * | 2022-09-26 | 2025-08-06 | Regcell Co., Ltd. | Induced regulatory t cells containing chimeric antigen receptor (car) |
-
2022
- 2022-11-22 MX MX2024006370A patent/MX2024006370A/es unknown
- 2022-11-22 EP EP22898585.9A patent/EP4438048A4/en active Pending
- 2022-11-22 CA CA3238860A patent/CA3238860A1/en active Pending
- 2022-11-22 KR KR1020247020426A patent/KR20240130083A/ko active Pending
- 2022-11-22 JP JP2023563705A patent/JPWO2023095802A1/ja active Pending
- 2022-11-22 TW TW111144652A patent/TW202334397A/zh unknown
- 2022-11-22 CN CN202280077889.6A patent/CN118591379A/zh active Pending
- 2022-11-22 US US18/713,036 patent/US20250352578A1/en active Pending
- 2022-11-22 WO PCT/JP2022/043221 patent/WO2023095802A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4438048A4 (en) | 2025-10-22 |
| CN118591379A (zh) | 2024-09-03 |
| WO2023095802A1 (ja) | 2023-06-01 |
| TW202334397A (zh) | 2023-09-01 |
| JPWO2023095802A1 (https=) | 2023-06-01 |
| CA3238860A1 (en) | 2023-06-01 |
| EP4438048A1 (en) | 2024-10-02 |
| US20250352578A1 (en) | 2025-11-20 |
| KR20240130083A (ko) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006370A (es) | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. | |
| MX2021012461A (es) | Procesos para preparar y usar un secretoma derivado de células madre mesenquimales. | |
| MX2021013713A (es) | Celulas pluripotentes modificadas. | |
| AU2019378883A8 (en) | Fusosome compositions for T cell delivery | |
| CO2020005810A2 (es) | Acceso aleatorio con conmutación de parte de ancho de banda | |
| AR111835A1 (es) | Composiciones estables de inoculantes que comprenden aceites vegetales metilados | |
| CR20240094A (es) | Composiciones estabilizadas | |
| BR112014018145A8 (pt) | Dispositivo de computação móvel, e respectivo sistema | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| BR112019001727A2 (pt) | refino de feixe para feixes ativos e candidatos | |
| MX2020006997A (es) | Metodo y dispositivo de comunicacion inalambrica. | |
| BR112022009121A2 (pt) | Feixe padrão comum por grupo de portadora de componente | |
| MX2024006360A (es) | Celula t controlable por inducibilidad humana y metodo para prepararla. | |
| BR112022026113A2 (pt) | Comutação de parte de largura de banda | |
| MX383809B (es) | Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas. | |
| MX2020012497A (es) | Moduladores de la expresion de apol1. | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| BR112022010072A2 (pt) | Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor | |
| MX2021010152A (es) | Moduladores de la expresion de malat1. | |
| BR112023022913A2 (pt) | Medições de gerenciamento de recurso de rádio eficiente para equipamento de usuário de capacidade reduzida | |
| MX2022004443A (es) | Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes. | |
| CO2021016797A2 (es) | Composiciones de virus adenoasociadas para la transferencia del gen arsa y métodos de uso de las mismas | |
| MX2023007367A (es) | Metodos y sistemas para conjuntos de valvulas de jeringa mezcladoras. | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| AR133780A1 (es) | Procedimiento de reconfiguración en comunicación de múltiple conectividad |